IMRT and molecular biological approaches in radiotherapy for prostate cancer

European Journal of Cancer

Volumn 45, Issue SUPPL. 1, 2009, Pages 429-430

  Bristow, Robert G ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; KI 67 ANTIGEN; PROTEIN BAX; PROTEIN BNIP3; PROTEIN MDM2; PROTEIN P53; SURVIVIN;

ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RADIOSENSITIVITY; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN HEMISPHERE;

HUMANS; MALE; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, INTENSITY-MODULATED; TUMOR MARKERS, BIOLOGICAL;

EID: 70349099535     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(09)70077-2     Document Type: Article

References (14)

1. Nichol A.M., Warde P., and Bristow R.G. Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues. Cancer 104 5 (2005) 891-905
2. D'Ambrosio D.J., Pollack A., Harris E.E., et al. Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 70 3 (2008) 671-677
3. Ritter M., Forman J., Kupelian P., Lawton C., and Petereit D. Hypofractionation for prostate cancer. Cancer J 15 1 (2009) 1-6
4. Miles E.F., and Lee W.R. Hypofractionation for prostate cancer: a critical review. Semin Radiat Oncol 18 1 (2008) 41-47
5. Zhang M., Ho A., Hammond E.H., et al. Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610. Int J Radiat Oncol Biol Phys 73 4 (2009) 1033-1042
6. Ishkanian A.S., Mallof C.A., Ho J., et al. High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate (2009 Apr 6) [Epub ahead of print].
7. Woodward W.A., and Bristow R.G. Radiosensitivity of cancer-initiating cells and normal stem cells (or what the Heisenberg uncertainly principle has to do with biology). Semin Radiat Oncol 19 2 (2009) 87-95
8. Fan R., Kumaravel T.S., Jalali F., Marrano P., Squire J.A., and Bristow R.G. Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. Cancer Res 64 23 (2004) 8526-8533
9. Damaraju S., Murray D., Dufour J., et al. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res 12 8 (2006) 2545-2554
10. Burri R.J., Stock R.G., Cesaretti J.A., et al. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiat Res 170 1 (2008) 49-59
11. Carnell D.M., Smith R.E., Daley F.M., Saunders M.I., Bentzen S.M., and Hoskin P.J. An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: implications for radioresistance. Int J Radiat Oncol Biol Phys 65 1 (2006) 91-99
12. Chan N., Milosevic M., and Bristow R.G. Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future Oncol 3 3 (2007) 329-341
13. Vergis R., Corbishley C.M., Norman A.R., et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 9 4 (2008) 342-351
14. Bristow R.G., and Hill R.P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8 3 (2008) 180-192